Live Breaking News & Updates on Boehringer Ingelheim Animal Health In Duluth

Jardiance® associated with a total cost of care savings of more than 20%, according to results from an outcomes-based agreement between Boehringer Ingelheim and Highmark
Share Article
Highmark and Boehringer Ingelheim announced positive results from their outcomes-based agreement, which showed that adults with type 2 diabetes and known cardiovascular disease who took Jardiance® (empagliflozin) had a lower annual total cost of care compared with those prescribed other branded or generic anti-hyperglycemic medications. Patients on Jardiance demonstrated a reduction in medical costs of over 30%. Factoring in both medical and pharmacy costs, the overall total cost of care reduction was more than 20% for patients on Jardiance. ....

United States , West Virginia , Kayse Reitmeyer , Eli Lilly , Leilyn Perri , Blue Cross Shield Association , Boehringer Ingelheim Pharmaceuticals Inc , Health Plan , Boehringer Ingelheim , Highmark Inc , Boehringer Ingelheim Animal Health In Duluth , Boehringer Ingelheim Corporation , Animal Health , Highmark Health , Boehringer Ingelheim Fremont Inc , Pharmacy Contracting , Important Safety Information , Christine Marsh , Market Access , Boehringer Ingelheim Pharmaceuticals , Cardiovascular Disease , Prescribing Information , Health Plans , Blue Cross Shield Affiliated , Human Pharma , Biopharmaceutical Contract ,